- Sanofi to invest $40 million at an as-converted price of $7.44 per share of common stock- - Sanofi to...
WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage...
WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage...
– Enrollment completed for Phase 2 trial evaluating iluzanebart in ALSP; Next data readout planned for Q3 2024...
- Findings from ILLUMINATE Natural History Study show that MRI and fluid biomarkers are emerging as key...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.